BioArctic’s lead compound has the potential to become the first disease-modifying treatment for Alzheimer’s, and so far the company’s journey has involved FDA approvals, a successful deal with AbbVie, collaborations with universities – and not least, the hiring of a very dedicated CEO.
Fo